According to transcriptome analysis, Conoidin A alleviates psoriasis like lesions by inhibiting Prx II to regulate keratinocyte apoptosis

Since the depletion of Prx II significantly reduced psoriatic symptoms in mice, Conoidin A, an inhibitor of Prx II was employed to evaluate the possibility of exploiting Prx II as a potential therapeutic target for the disease. Skin on the back of Prx II+/+ mice was treated with IMQ alone for 4 days, followed by combined treatment with 5 mg/kg of Conoidin A and IMQ for an additional 3 days. Mice in the Conoidin A treatment group displayed a significantly lesser degree of skin surface erythema, scaling, and psoriatic lesions as compared to those in the IMQ alone treatment group . Histological examination and statistical analysis revealed significantly thinner skin in mice that additionally received Conoidin A as compared to those that only received IMQ . This indicates that Prx II may serve as a potential therapeutic target for the development of effective treatments for psoriasis.